Clinical Trials Browser

Phase 1 × BRAF V600E-mutated /MSS Metastatic Colorectal Cancer × camrelizumab × Clear all

NCT05019534 2022-05-19

Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

Phase 1 Unknown

Gastrointestinal

BRAF V600E-mutated /MSS Metastatic Colorectal Cancer